Publications

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit

Journal of Neuro-Oncology ,

Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.

ASCO Meeting Library,

Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.

ASCO Meeting Library,

Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).

ASCO Meeting Library,

Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.

ASCO Meeting Library,

Cellworks Omics Biology Model (CBM) to predict therapy response and identify novel biomarkers for 5FU-based combination therapy in gastric cancer patients.

ASCO Meeting Library,

Cellworks Omics Biology Modeling (CBM) to predict therapy response and identifies novel biomarkers for carboplatin/cisplatin along with pemetrexed in NSCLC patients.

ASCO Meeting Library,

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: myCare-020-01

Blood Journal,

STAY INFORMED

Top